CEL-SCI Corporation Announces $6.0 Million Public Offering
Sichenzia Ross Friedman Ference LLP Represents CEL-SCI Corporation on $6.0 Million Public Offering
New York, NY – October 29, 2014 – GLOBAL NEWSWIRE – New York based securities and corporate law firm Sichenzia Ross Friedman Ference LLP announced that it has advised Laidlaw & Co. (UK) Ltd. as the Lead Underwriter in a $6 million public Public Offering of CEL-SCI Corporation (NYSE MKT: CVM), a late-stage biotechnology company focused on oncology research and drug development. The underwriting was pursuant to a prospectus supplement to an effective S-3 registration statement. The offering consisted of common stock and warrants at a combined price of $0.76 per unit. Pursuant to the offering, CEL-SCI issued one warrant to purchase common stock for every four shares sold. The warrants have an exercise price of $1.25 per unit. The Sichenzia Ross Friedman Ference LLP team was led by Partner Richard A. Friedman and Associate Stephen Cohen.
- Sichenzia Ross Ference LLP Represents High Tide Inc. in the $20.64 million acquisition of Fab Nutrition, LLC - May 11, 2021
- Sichenzia Ross Ference LLP Represents Aegis Capital in $48.3 Million Underwritten Public Offering of Farmmi, Inc. - May 3, 2021
- Sichenzia Ross Ference LLP Wins Appeal Before the Second Circuit in a Lawsuit Brought By Investors in Connection with a Private Placement - April 30, 2021